Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia

Relapse-Free Survival Is Determined by Karyotype and Comorbidities

Hesham M Eissa, Ted A. Gooley, Mohamed L. Sorror, Franchesca Nguyen, Bart L. Scott, Kristine Doney, Keith R. Loeb, Paul J. Martin, John M. Pagel, Jerry P. Radich, Brenda M. Sandmaier, E. Houston Warren, Rainer Storb, Frederick R. Appelbaum, H. Joachim Deeg

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Hematopoietic cell transplantation (HCT) offers potentially curative therapy for chronic myelomonocytic leukemia (CMML). We evaluated HCT outcomes in 85 patients with CMML, 1.0-69.1 (median 51.7) years of age, with follow-up extending to 19 years. CMML was considered de novo in 71 and secondary in 14 patients. Conditioning regimens were of various intensities. Thirty-eight patients had related (34 HLA identical), and 47 (39 HLA matched) unrelated donors. The source of stem cells was marrow in 32 and peripheral blood progenitor cells in 53 patients. Acute graft-versus-host disease (aGVHD) grades II-IV occurred in 72% and chronic GVHD (cGVHD) in 26% of patients. Relapse incidence was 27% at 10 years. Relapse correlated with increasing scores by the MD Anderson prognostic score (P = .01). The major causes of death were relapse and infections ±GVHD. Progression-free survival (PFS) was 38% at 10 years. Mortality was negatively correlated with pre-HCT hematocrit (P = .007), and increased with high-risk cytogenetics (P = .02), higher HCT Comorbidity Index (P = .0008), and increased age (P = .02). WHO classification did not statistically significantly affect outcome. Thus, a proportion of patients with CMML have lasting remissions following allogeneic HCT and appear to be cured of their disease.

Original languageEnglish (US)
Pages (from-to)908-915
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2011

Fingerprint

Leukemia, Myelomonocytic, Chronic
Cell Transplantation
Karyotype
Comorbidity
Recurrence
Survival
Stem Cells
Unrelated Donors
Graft vs Host Disease
Hematocrit
Cytogenetics
Disease-Free Survival
Cause of Death
Blood Cells
Bone Marrow
Mortality
Incidence
Infection

Keywords

  • CMML
  • Comorbidity
  • Cytogenetics
  • Hematopoietic cell transplantation

Cite this

Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia : Relapse-Free Survival Is Determined by Karyotype and Comorbidities. / Eissa, Hesham M; Gooley, Ted A.; Sorror, Mohamed L.; Nguyen, Franchesca; Scott, Bart L.; Doney, Kristine; Loeb, Keith R.; Martin, Paul J.; Pagel, John M.; Radich, Jerry P.; Sandmaier, Brenda M.; Warren, E. Houston; Storb, Rainer; Appelbaum, Frederick R.; Deeg, H. Joachim.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 6, 01.06.2011, p. 908-915.

Research output: Contribution to journalArticle

Eissa, HM, Gooley, TA, Sorror, ML, Nguyen, F, Scott, BL, Doney, K, Loeb, KR, Martin, PJ, Pagel, JM, Radich, JP, Sandmaier, BM, Warren, EH, Storb, R, Appelbaum, FR & Deeg, HJ 2011, 'Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities', Biology of Blood and Marrow Transplantation, vol. 17, no. 6, pp. 908-915. https://doi.org/10.1016/j.bbmt.2010.09.018
Eissa, Hesham M ; Gooley, Ted A. ; Sorror, Mohamed L. ; Nguyen, Franchesca ; Scott, Bart L. ; Doney, Kristine ; Loeb, Keith R. ; Martin, Paul J. ; Pagel, John M. ; Radich, Jerry P. ; Sandmaier, Brenda M. ; Warren, E. Houston ; Storb, Rainer ; Appelbaum, Frederick R. ; Deeg, H. Joachim. / Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia : Relapse-Free Survival Is Determined by Karyotype and Comorbidities. In: Biology of Blood and Marrow Transplantation. 2011 ; Vol. 17, No. 6. pp. 908-915.
@article{73fb6038f4f04d648a7d7dcf9a9774f0,
title = "Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities",
abstract = "Hematopoietic cell transplantation (HCT) offers potentially curative therapy for chronic myelomonocytic leukemia (CMML). We evaluated HCT outcomes in 85 patients with CMML, 1.0-69.1 (median 51.7) years of age, with follow-up extending to 19 years. CMML was considered de novo in 71 and secondary in 14 patients. Conditioning regimens were of various intensities. Thirty-eight patients had related (34 HLA identical), and 47 (39 HLA matched) unrelated donors. The source of stem cells was marrow in 32 and peripheral blood progenitor cells in 53 patients. Acute graft-versus-host disease (aGVHD) grades II-IV occurred in 72{\%} and chronic GVHD (cGVHD) in 26{\%} of patients. Relapse incidence was 27{\%} at 10 years. Relapse correlated with increasing scores by the MD Anderson prognostic score (P = .01). The major causes of death were relapse and infections ±GVHD. Progression-free survival (PFS) was 38{\%} at 10 years. Mortality was negatively correlated with pre-HCT hematocrit (P = .007), and increased with high-risk cytogenetics (P = .02), higher HCT Comorbidity Index (P = .0008), and increased age (P = .02). WHO classification did not statistically significantly affect outcome. Thus, a proportion of patients with CMML have lasting remissions following allogeneic HCT and appear to be cured of their disease.",
keywords = "CMML, Comorbidity, Cytogenetics, Hematopoietic cell transplantation",
author = "Eissa, {Hesham M} and Gooley, {Ted A.} and Sorror, {Mohamed L.} and Franchesca Nguyen and Scott, {Bart L.} and Kristine Doney and Loeb, {Keith R.} and Martin, {Paul J.} and Pagel, {John M.} and Radich, {Jerry P.} and Sandmaier, {Brenda M.} and Warren, {E. Houston} and Rainer Storb and Appelbaum, {Frederick R.} and Deeg, {H. Joachim}",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.bbmt.2010.09.018",
language = "English (US)",
volume = "17",
pages = "908--915",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia

T2 - Relapse-Free Survival Is Determined by Karyotype and Comorbidities

AU - Eissa, Hesham M

AU - Gooley, Ted A.

AU - Sorror, Mohamed L.

AU - Nguyen, Franchesca

AU - Scott, Bart L.

AU - Doney, Kristine

AU - Loeb, Keith R.

AU - Martin, Paul J.

AU - Pagel, John M.

AU - Radich, Jerry P.

AU - Sandmaier, Brenda M.

AU - Warren, E. Houston

AU - Storb, Rainer

AU - Appelbaum, Frederick R.

AU - Deeg, H. Joachim

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Hematopoietic cell transplantation (HCT) offers potentially curative therapy for chronic myelomonocytic leukemia (CMML). We evaluated HCT outcomes in 85 patients with CMML, 1.0-69.1 (median 51.7) years of age, with follow-up extending to 19 years. CMML was considered de novo in 71 and secondary in 14 patients. Conditioning regimens were of various intensities. Thirty-eight patients had related (34 HLA identical), and 47 (39 HLA matched) unrelated donors. The source of stem cells was marrow in 32 and peripheral blood progenitor cells in 53 patients. Acute graft-versus-host disease (aGVHD) grades II-IV occurred in 72% and chronic GVHD (cGVHD) in 26% of patients. Relapse incidence was 27% at 10 years. Relapse correlated with increasing scores by the MD Anderson prognostic score (P = .01). The major causes of death were relapse and infections ±GVHD. Progression-free survival (PFS) was 38% at 10 years. Mortality was negatively correlated with pre-HCT hematocrit (P = .007), and increased with high-risk cytogenetics (P = .02), higher HCT Comorbidity Index (P = .0008), and increased age (P = .02). WHO classification did not statistically significantly affect outcome. Thus, a proportion of patients with CMML have lasting remissions following allogeneic HCT and appear to be cured of their disease.

AB - Hematopoietic cell transplantation (HCT) offers potentially curative therapy for chronic myelomonocytic leukemia (CMML). We evaluated HCT outcomes in 85 patients with CMML, 1.0-69.1 (median 51.7) years of age, with follow-up extending to 19 years. CMML was considered de novo in 71 and secondary in 14 patients. Conditioning regimens were of various intensities. Thirty-eight patients had related (34 HLA identical), and 47 (39 HLA matched) unrelated donors. The source of stem cells was marrow in 32 and peripheral blood progenitor cells in 53 patients. Acute graft-versus-host disease (aGVHD) grades II-IV occurred in 72% and chronic GVHD (cGVHD) in 26% of patients. Relapse incidence was 27% at 10 years. Relapse correlated with increasing scores by the MD Anderson prognostic score (P = .01). The major causes of death were relapse and infections ±GVHD. Progression-free survival (PFS) was 38% at 10 years. Mortality was negatively correlated with pre-HCT hematocrit (P = .007), and increased with high-risk cytogenetics (P = .02), higher HCT Comorbidity Index (P = .0008), and increased age (P = .02). WHO classification did not statistically significantly affect outcome. Thus, a proportion of patients with CMML have lasting remissions following allogeneic HCT and appear to be cured of their disease.

KW - CMML

KW - Comorbidity

KW - Cytogenetics

KW - Hematopoietic cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=79956054105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956054105&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.09.018

DO - 10.1016/j.bbmt.2010.09.018

M3 - Article

VL - 17

SP - 908

EP - 915

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -